- Home
- CTW vs SRZN Comparison
CTW vs SRZN Comparison
Compare CTW & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTW
- SRZN
- Stock Information
- Founded
- CTW 2013
- SRZN 2015
- Country
- CTW Japan
- SRZN United States
- Employees
- CTW N/A
- SRZN N/A
- Industry
- CTW EDP Services
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- CTW Technology
- SRZN Health Care
- Exchange
- CTW Nasdaq
- SRZN Nasdaq
- Market Cap
- CTW 131.0M
- SRZN 120.0M
- IPO Year
- CTW 2025
- SRZN N/A
- Fundamental
- Price
- CTW $2.35
- SRZN $12.72
- Analyst Decision
- CTW
- SRZN Strong Buy
- Analyst Count
- CTW 0
- SRZN 2
- Target Price
- CTW N/A
- SRZN $38.50
- AVG Volume (30 Days)
- CTW 285.0K
- SRZN 81.9K
- Earning Date
- CTW 11-17-2025
- SRZN 11-07-2025
- Dividend Yield
- CTW N/A
- SRZN N/A
- EPS Growth
- CTW N/A
- SRZN N/A
- EPS
- CTW N/A
- SRZN N/A
- Revenue
- CTW $76,194,020.00
- SRZN $3,604,000.00
- Revenue This Year
- CTW N/A
- SRZN N/A
- Revenue Next Year
- CTW N/A
- SRZN N/A
- P/E Ratio
- CTW $51.43
- SRZN N/A
- Revenue Growth
- CTW 8.71
- SRZN N/A
- 52 Week Low
- CTW $1.71
- SRZN $5.90
- 52 Week High
- CTW $4.88
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- CTW N/A
- SRZN 49.06
- Support Level
- CTW N/A
- SRZN $12.12
- Resistance Level
- CTW N/A
- SRZN $13.31
- Average True Range (ATR)
- CTW 0.00
- SRZN 0.83
- MACD
- CTW 0.00
- SRZN -0.06
- Stochastic Oscillator
- CTW 0.00
- SRZN 46.99
About CTW CTW Cayman Class A Ordinary Shares
CTW Cayman is a web-based gaming platform, offering players an immersive digital space through flagship HTML5 platform, G123.jp. The company's primary focus is to serve game developers by providing a comprehensive platform that helps them generate revenue and reach a global audience. The platform offers a diverse selection of free-to-play games inspired by popular Japanese animations and it hosts 28 games, with 9 additional titles in pre-registration.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).